6833 (6833) Fair Value & Analysis

Healthcare · Market cap HK$325M

6 6833 6833 · HK

PriceHK$0.1790

Fair ValueHK$0.3800

Upside+112.3%

Quality49/100

Watch 6833 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.2800 – HK$0.4700

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price +5.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1550 – HK$0.2676 · fair‑value band HK$0.2800 – HK$0.4700 · the HK$0.1790 price screens below the HK$0.3800 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6833 (6833) currently trades at HK$0.1790, while our model-based Fair Value estimate is HK$0.3800 — implying the stock looks roughly 112.3% undervalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 6833 generated revenue of HK$2.1B at a net margin of 1.7%. Revenue declined 31.3% year over year. It earns a return on equity of 5.1%. The balance sheet holds a net cash position of HK$191M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$2.1B

Revenue growth (YoY) -31.3%

Net margin 1.7%

Return on equity 5.1%

Free cash flow HK$160M FY2025

P/E ratio 8.0

More key figures

Operating margin 2.6%

EPS (TTM) HK$0.0100

Dividend yield 1.3%

EPS growth (YoY) -39.4%

Net cash HK$191M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6833 reported revenue of HK$2.1B in FY2025 versus HK$2.0B in FY2021, a compound +0.7%/yr. Reported net income was HK$34.9M in FY2025, compounding −28.7%/yr from FY2021.

Revenue +0.7%/yr

FY21 HK$2.0B

FY22 HK$2.3B

FY23 HK$2.5B

FY24 HK$2.8B

FY25 HK$2.1B

Net income −28.7%/yr

FY21 HK$135M

FY22 HK$69.5M

FY23 HK$42.4M

FY24 HK$42.0M

FY25 HK$34.9M

Is 6833 fairly valued? → Check now

Similar stocks

6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation M1CK34	R$999.49	R$1,236	+24%
Cencora, Inc C1CO34	R$707.04	R$79.88	-89%
Cardinal Health, Inc CAH	$201.74	$92.07	-54%
Sigma Healthcare Limited SIGGF	$2.35	$0.6300	-73%
SIG SIG	A$2.92	A$1.20	-59%
Shanghai Pharmaceuticals Holding 601607	¥15.96	¥45.15	+183%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6833 (6833) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.3800 versus a price of HK$0.1790 — about +112% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 6833?

Our model-based fair value for 6833 is HK$0.3800 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.1790.

What is the quality score of 6833?

6833 has a Quality Score of 49/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6833 (6833)?

6833 reported trailing-twelve-month revenue of about HK$2.1B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6833?

The net profit margin of 6833 is about 1.7%, meaning it keeps roughly 1.7% of revenue as net income. Based on the latest reported figures.

Does 6833 pay a dividend?

6833 currently shows a dividend yield of about 1.26% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.